Timeline: India's coronavirus vaccine approved by drugs experts
By Sudarshan Varadhan and Krishna N. Das CHENNAI/NEW DELHI (Reuters) - India's drugs regulator on Saturday recommended for emergency use a locally developed coronavirus vaccine called COVAXIN, which is expected to be a backup to the AstraZeneca/Oxford shot. COVAXIN has been developed by Bharat Biotech, a company based in Hyderabad, with backing from the state-run Indian Council of Medical Research (ICMR).
coronavirus vaccine approved by drugs experts" src="https://images.firstpost.com/wp-content/uploads/reuters/01-2021/04/2021-01-03T021651Z_2_LYNXMPEH0200N_RTROPTP_2_HEALTH-CORONAVIRUS-INDIA-VACCINE.jpg" alt="Timeline Indias coronavirus vaccine approved by drugs experts" width="300" height="225" />
By Sudarshan Varadhan and Krishna N. Das
CHENNAI/NEW DELHI (Reuters) - India's drugs regulator on Saturday recommended for emergency use a locally developed coronavirus vaccine called COVAXIN, which is expected to be a backup to the AstraZeneca/Oxford shot.
COVAXIN has been developed by Bharat Biotech, a company based in Hyderabad, with backing from the state-run Indian Council of Medical Research (ICMR).
Not much is known about the safety and efficacy of COVAXIN. The company says it has submitted all data to the drugs regulator.
The head of India's drugs regulator is expected to share details about it at a news conference on Sunday, when its formal approval is likely to be announced.
Here are some major developments related to COVAXIN:
June 30, 2020 - The Drugs Controller General of India (DGCI) approves COVAXIN for human trials, making it the country's first domestic vaccine candidate. (https://reut.rs/3hJ1j40)
July 3 - An official at ICMR, India's top clinical research agency, says in a leaked letter it envisages launching a coronavirus vaccine by Aug. 15, India's independence day, leading to questions from some health experts about the short timeline.
The same day, Bharat Biotech shares its target of producing up to 300 million doses of the vaccine if its trials succeed.
July 4 - ICMR says its decision to fast-track development of a potential coronavirus vaccine is in line with international standards.
Oct 23 - Bharat Biotech says it is in discussions with more than 10 countries that have shown an interest in its vaccine candidate. It says Phase 1 and 2 trials have found the vaccine to be safe.
Nov 01 - Bharat Biotech says it is planning to launch the vaccine in the second quarter of 2021.
Nov 16 - Bharat Biotech says it is starting phase III trials.
Nov 20 - Bharat Biotech offers Brazil the vaccine and a possible technology-transfer partnership.
Dec 07 - Bharat Biotech seeks emergency use approval for COVAXIN.
Dec 22 - U.S.-based drug developer Ocugen Inc says it has partnered with Bharat Biotech to co-develop the vaccine candidate for the U.S. market.
Jan 2 - Experts at India's drug regulator approve the vaccine "for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, specially in the context of infection by mutant strains".
Bharat Biotech says it has recruited 23,000 volunteers out of its target of 26,000 for an ongoing Phase-3 trial of COVAXIN in India that began in mid-November. It is the largest Phase III efficacy trial conducted for any vaccine in India.
(Reporting by Sudarshan Varadhan in CHENNAI and Krishna N. Das in NEW DELHI; Editing by Christina Fincher)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Aditya Kalra NEW DELHI (Reuters) - India's tobacco industry will object to a proposal to ban smoking zones in hotels and prohibit advertising at cigarette kiosks as the government steps up anti-smoking efforts, two executives said on Wednesday. India has over the years introduced tobacco controls and launched campaigns to deter its use, but enforcement of the law has been a challenge.
HONG KONG (Reuters) - Over 50 pro-democratic activists in Hong Kong were arrested on Wednesday for breaking the city's contentious national security law, local media reported, in the biggest crackdown yet against the democratic opposition under the new law. The arrests in the Asian financial hub included well known democratic figures and former lawmakers James To, Lam Cheuk Ting and Lester Shum, according to the Democratic Party's Facebook page and public broadcaster RTHK. Police did not immediately respond to requests for comment.
BRASILIA (Reuters) - Brazil's syringe manufacturers said on Tuesday they will supply 30 million syringes and needles for the country's COVID-19 vaccination program after the government said it would requisition surplus supplies. Executives of the three main manufacturers met with President Jair Bolsonaro at the Health Ministry and it was agreed that each would supply 10 million syringes to cover the initial stages of the vaccination plan.